8 / 11
Page 18
Notes:
allied
academies
August 23-24, 2018 | London, UK
Hematology and Oncology
2
nd
International Conference on
Journal of Hematology and Blood Disorder | Volume 2
Cell-mediated immunotherapy of cancer by intentionally mismatched donor lymphocytes
Shimon Slavin
Biotherapy International, Israel
C
hemotherapy-resistant hematopoietic malignancies and
metastatic solid tumors remain incurable due to residual
multi-drug resistant cancer cells after conventional anti-cancer
modalities and cancer stem cells that are a priori resistant
to available anti-cancer modalities. We have previously
documented that patients with hematological malignancies
fully resistant to myeloablative chemoradiotherapy may be
cured by donor lymphocyte infusion [DLI] following failure of
myeloablative stem cell transplantation (SCT), indicating that
alloreactive lymphocytes can eliminate “the last cancer cell”
regardless of resistance to all available anti-cancer modalities.
When immunotherapy by donor lymphocytes is applied
following allogeneic SCT, elimination of resistant cancer cells
may be accomplished at the cost of hazardous, not infrequently
fatal, acute and chronic graft-vs-host disease [GVHD]. We
have developed a new approach for elimination of resistant
malignant cells using safe outpatient procedure based on the
use of intentionally mismatched, related haploidentical or
even unrelated donor lymphocytes, activated in vitro and in
vivo with low dose interleukin 2 [IL-2] including activated T &
NK cells. No GVHD develops because intentionally mismatched
killer cells are always rejected after less than 7-10 days, before
there is any chance for GVHD to develop. IL-2 activated
intentionally mismatched donor lymphocytes, including T cells
and NK cells, can induce very potent anti-cancer effects without
causing GVHD. Anti-cancer effects of intentionally mismatched
donor lymphocytes can be further amplified by targeting
killer cells against residual malignant cells using monoclonal
and bispecific antibodies against antigens over-expressed on
targeted malignant cells. In conclusion, accordingly, based on
our successful cumulative pre-clinical experimental data and
ongoing clinical experience, clinical application of intentionally
mismatched killer cells at the stage of minimal residual disease
may represent a simple, safe and cost-effective procedure that
my result in cure in patients with otherwise incurable cancer.
Speaker Biography
Shimon Slavin is the professor of medicine and he is also the medical and scientific director
at the Biotherapy International.
e:
slavinmd@gmail.com